142 related articles for article (PubMed ID: 35132688)
1. Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy.
Wei Z; Yi Y; Luo Z; Gong X; Jiang Y; Hou D; Zhang L; Liu Z; Wang M; Wang J; Guo R; Yang J; Wang L; Wang H; Zhao Y
Adv Mater; 2022 Apr; 34(17):e2108167. PubMed ID: 35132688
[TBL] [Abstract][Full Text] [Related]
2. Phosphorous Dendron Micelles as a Nanomedicine Platform for Cooperative Tumor Chemoimmunotherapy via Synergistic Modulation of Immune Cells.
Zhan M; Qiu J; Fan Y; Chen L; Guo Y; Wang Z; Li J; Majoral JP; Shi X
Adv Mater; 2023 Jan; 35(3):e2208277. PubMed ID: 36300810
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
5. Heating tumors with tumor cell-derived nanoparticles to enhance chemoimmunotherapy for colorectal cancer.
Li XY; Li RH; Cong JZ; Liu WS; Zhang Y; Guan HL; Zhu LL; Chen K; Pang LY; Jin H
Nanomedicine (Lond); 2024 Mar; 19(7):561-579. PubMed ID: 38265008
[No Abstract] [Full Text] [Related]
6. Combinational Chemoimmunotherapy for Breast Cancer by Codelivery of Doxorubicin and PD-L1 siRNA Using a PAMAM-Incorporated Liposomal Nanoplatform.
Hu Q; Yao J; Wang X; Wang Y; Fu X; Ma J; Lin H; Xu J; Shen L; Yu X
ACS Appl Mater Interfaces; 2022 Feb; 14(7):8782-8792. PubMed ID: 35138103
[TBL] [Abstract][Full Text] [Related]
7. Transformable Honeycomb-Like Nanoassemblies of Carbon Dots for Regulated Multisite Delivery and Enhanced Antitumor Chemoimmunotherapy.
Hou L; Chen D; Wang R; Wang R; Zhang H; Zhang Z; Nie Z; Lu S
Angew Chem Int Ed Engl; 2021 Mar; 60(12):6581-6592. PubMed ID: 33305859
[TBL] [Abstract][Full Text] [Related]
8. Selenium-Containing Nanoparticles Combine the NK Cells Mediated Immunotherapy with Radiotherapy and Chemotherapy.
Gao S; Li T; Guo Y; Sun C; Xianyu B; Xu H
Adv Mater; 2020 Mar; 32(12):e1907568. PubMed ID: 32053267
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted and multi-stimuli responsive drug delivery system for near-infrared light induced chemo-phototherapy and photoacoustic tomography.
Feng Q; Zhang Y; Zhang W; Shan X; Yuan Y; Zhang H; Hou L; Zhang Z
Acta Biomater; 2016 Jul; 38():129-42. PubMed ID: 27090593
[TBL] [Abstract][Full Text] [Related]
10. Tandem Chemoimmunotherapy by a Cascade-Responsive Molecular Prodrug.
Yang Z; Luo X; Lin Y; Huang J; Lin H; Gao J
ACS Chem Biol; 2022 Apr; 17(4):762-767. PubMed ID: 35285234
[TBL] [Abstract][Full Text] [Related]
11. Cascade-amplifying synergistic effects of chemo-photodynamic therapy using ROS-responsive polymeric nanocarriers.
Sun CY; Cao Z; Zhang XJ; Sun R; Yu CS; Yang X
Theranostics; 2018; 8(11):2939-2953. PubMed ID: 29896295
[TBL] [Abstract][Full Text] [Related]
12. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
13. Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy.
Wang Y; Wang Z; Chen B; Yin Q; Pan M; Xia H; Zhang B; Yan Y; Jiang Z; Zhang Q; Wang Y
Nano Lett; 2021 May; 21(10):4371-4380. PubMed ID: 33984236
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine-Combined Immunotherapy for Cancer.
Huang S; Zhao Q
Curr Med Chem; 2020; 27(34):5716-5729. PubMed ID: 31250752
[TBL] [Abstract][Full Text] [Related]
15. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
Zheng G; Zheng M; Yang B; Fu H; Li Y
Biomed Pharmacother; 2019 Aug; 116():109006. PubMed ID: 31152925
[TBL] [Abstract][Full Text] [Related]
16. PEGylated Poly(α-lipoic acid) Loaded with Doxorubicin as a pH and Reduction Dual Responsive Nanomedicine for Breast Cancer Therapy.
Yang H; Shen W; Liu W; Chen L; Zhang P; Xiao C; Chen X
Biomacromolecules; 2018 Nov; 19(11):4492-4503. PubMed ID: 30346147
[TBL] [Abstract][Full Text] [Related]
17. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
18. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin nanomedicine based on ginsenoside Rg1 with alleviated cardiotoxicity and enhanced antitumor activity.
Li C; Gou X; Gao H
Nanomedicine (Lond); 2021 Dec; 16(29):2587-2604. PubMed ID: 34719938
[TBL] [Abstract][Full Text] [Related]
20. Design of light/ROS cascade-responsive tumor-recognizing nanotheranostics for spatiotemporally controlled drug release in locoregional photo-chemotherapy.
Zuo W; Chen D; Fan Z; Chen L; Zhu Z; Zhu Q; Zhu X
Acta Biomater; 2020 Jul; 111():327-340. PubMed ID: 32434075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
